Search the Newsreel

OKYO Pharma (OKYO) director buys 5,000 shares in open market

Tokyo Plast International Share Price Outlook: Where It Could Be in 3 Years

Tokyo Plast Consolidated June 2026 Net Sales at Rs 19.83 crore, up 8.9% Y-o-Y

OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday

Tokyo Plast International accepts resignation of Company Secretary Sonal Gandhi

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYO Pharma Limited announced its participation in the BTIG Biotechnology Conference 2026, which will take place virtually on July 28-29, 2026. Key company representatives, including CEO Robert J. Dempsey and CFO Keeren Shah, will be available for one-on-one meetings. The clinical-stage biopharmaceutical company is …

Japan Earnings Wrap: Tokyo Electron, Mizuho Financial Rise, Nomura Research Slides

OKYO Pharma (OKYO) CSO discloses stock and option positions

OKYO Pharma's Chief Scientific Officer, Rajkumar V. Patil, has disclosed his initial holdings of common stock and stock options. As of March 18, 2026, Patil holds 16,667 shares of common stock directly and multiple stock option awards with various exercise prices and expiration dates …

TSMC's Kumamoto Output Was Under 3%, But Tokyo Electron Kyushu's 91% Global Share Was the Supply Chain's True Weak Point

OKYO Pharma CSO purchases additional shares at $1.49

OKYO Pharma's Chief Scientific Officer, Raj Patil, recently purchased 3,363 additional ordinary shares of the company at $1.49 per share, increasing his total holdings to 20,030 shares. The clinical-stage biopharmaceutical company is preparing to start a global Phase 3 clinical trial in the second …

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma announced that its Chief Scientific Officer, Raj Patil, PhD, increased his holdings by purchasing 3,363 ordinary shares, bringing his total to 20,030 shares. The clinical-stage biopharmaceutical company is developing therapies for neuropathic corneal pain and anterior segment eye diseases, with a global …

OKYO Pharma scientist's holdings reach 20,030 shares after purchase

OKYO Pharma's Chief Scientific Officer, Raj Patil, has increased his stake in the company by purchasing 3,363 ordinary shares at $1.49 each, bringing his total holding to 20,030 shares. The company, a clinical-stage biopharmaceutical firm, is developing therapies for neuropathic corneal pain (NCP) and …

OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial

OKYO Pharma's Chief Scientific Officer, Raj Patil, PhD, increased his holdings by purchasing 3,363 ordinary shares at $1.49 per share, bringing his total to 20,030 shares. The clinical-stage biopharmaceutical company, which focuses on neuropathic corneal pain and anterior segment eye diseases, plans to initiate …

OKYO Pharma CSO buys shares

OKYO Pharma Ltd's Chief Scientific Officer, Raj Patil, has increased his holdings in the company by purchasing 3,363 ordinary shares at $1.49 each on Nasdaq. This transaction brings his total stake to 20,030 shares. The article states that Proactive has a commercial relationship with …

Why is Tokyo Electron stock tumbling today? By Investing.com

Why is Tokyo Electron stock tumbling today?

OKYO Pharma plans 111-patient Phase 3 corneal pain trial

OKYO Pharma, a clinical-stage biopharmaceutical company, announced its participation in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The company plans to initiate a global Phase 3 clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate …

OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference

OKYO Pharma (Nasdaq: OKYO) announced its participation in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026, where senior management will be available for one-on-one meetings. The company also revealed plans to initiate a global Phase 3 pivotal clinical trial in the second …

OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans

Tokyo Plast International Q1 Results: Standalone profit rises 289% YoY

OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase

OKYO Pharma Limited announced that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The company, a clinical-stage biopharmaceutical firm, is developing therapies for neuropathic corneal pain (NCP) and anterior segment eye …

OKYO Pharma Director's Holding Reaches 35,201 Shares

OKYO Pharma (Nasdaq: OKYO) announced that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares at $1.48 each, increasing his total holding to 35,201 shares. The company, a clinical-stage biopharmaceutical developer focusing on neuropathic corneal pain (NCP) and anterior segment eye diseases, plans to initiate …

OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares

OKYO Pharma's CEO, Robert J. Dempsey, purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share on July 23, 2026. This transaction was reported via an SEC Form 6-K filing. OKYO Pharma is a clinical-stage biopharmaceutical company focusing on therapies for …

OKYO Pharma says CEO purchased 15,000 shares

OKYO Pharma Ltd (NASDAQ:OKYO) announced that its CEO, Robert Dempsey, purchased 15,000 ordinary shares of the company. The shares were acquired on the Nasdaq at a price of $1.54 each, totaling approximately $23,100. This insider transaction highlights a personal investment by the CEO in …

OKYO Pharma (Nasdaq: OKYO) chair buys more shares, now owns 20.55%

OKYO Pharma's chairman, Gabriele Cerrone, through Panetta Partners Ltd, acquired an additional 22,500 ordinary shares at $1.45 per share, increasing his total beneficial ownership to 20.55% of the company's issued share capital. OKYO Pharma is a clinical-stage biopharmaceutical company focusing on neuropathic corneal pain …

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma announced that Gary S. Jacob, PhD, Chief Development Officer and Director, purchased 3,500 of the company's ordinary shares at $1.40 each, increasing his total holding to 112,420 shares. OKYO Pharma is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and other …

OKYO Pharma director lifts holding to 112,420 shares

OKYO Pharma's Chief Development Officer and Director, Gary S. Jacob, PhD, purchased 3,500 ordinary shares at $1.40 each, increasing his total holding to 112,420 shares. This transaction comes as the clinical-stage biopharmaceutical company plans to initiate a global Phase 3 pivotal trial for neuropathic …

OKYO Pharma (Nasdaq: OKYO) director adds 3,500 shares at $1.40

OKYO Pharma's Chief Development Officer and Director, Gary S. Jacob, PhD, purchased 3,500 ordinary shares of the company on Nasdaq at $1.40 per share, increasing his total holdings to 112,420 shares. The company is a clinical-stage biopharmaceutical firm focused on therapies for neuropathic corneal …

OKYO Pharma Plans Phase 3 Trial for Single-Dose Eye Pain Drug

OKYO Pharma's Chief Medical Officer, Flavio Mantelli, purchased 20,000 ordinary shares of the company at $1.40 per share. The company, a clinical-stage biopharmaceutical firm, announced plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year. This trial …

OKYO Pharma LTD

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference. Robert J. Dempsey, CEO, and Flavio Mantelli MD, PhD, CMO, will present on July 22, 2026. The company is developing therapies for neuropathic …

OKYO Pharma chairman increases stake to 20.51%

OKYO Pharma's Chairman, Gabriele Cerrone, has increased his stake in the company to 20.51% through Panetta Partners Ltd. He purchased an additional 25,000 ordinary shares at $1.40 each, bringing his total holdings to 10,851,416 ordinary shares. OKYO Pharma is a clinical-stage biopharmaceutical company listed …

OKYO Pharma (Nasdaq: OKYO) to present and plan Phase 3 NCP trial

OKYO Pharma will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, where its CEO and CMO will discuss the company's progress. Concurrently, OKYO is planning to initiate a global Phase 3 pivotal clinical trial in the latter half …

OKYO Pharma (Nasdaq: OKYO) chair lifts stake as Phase 3 NCP trial nears

OKYO Pharma's Chairman, Gabriele Cerrone, through Panetta Partners Ltd, has increased his stake in the company to 20.51% by purchasing an additional 25,000 ordinary shares at $1.40 each. This acquisition brings his total holding to 10,851,416 ordinary shares. The biotechnology company is nearing the …